Autism spectrum disorder in an adolescent with deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase of fatty acids caused by a mutation in the HADHA gene in a homozygous state (presentation of a clinical case)

Autism spectrum disorder in an adolescent with deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase of fatty acids caused by a mutation in the HADHA gene in a homozygous state (presentation of a clinical case)

 

Authors

 

O.V. Shushpanova

Mental Health Research Center, Russian Academy of Sciences, Moscow, Russian Federation

I.S. Boksha

Mental Health Research Center, Russian Academy of Sciences, Moscow, Russian Federation

S.A. Zozulya

Mental Health Research Center, Russian Academy of Sciences, Moscow, Russian Federation

 

https://doi.org/10.26617/1810-3111-2025-4(129)-105-116

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2025; 4 (129):  105-116.

 

Abstract

Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency is a congenital, inherited, autosomal recessive disorder of fatty acid metabolism characterized by impaired ability to sequentially metabolize long-chain fatty acids to acetyl-CoA molecules via mitochondrial beta-oxidation. Hypofunction of long-chain 3-hydroxyacyl-CoA dehydrogenase causes disturbances of varying severity in vital organs and systems at the macro- and microlevels, and leads to the development of mental disorders with cognitive impairment, which can be classified as autism spectrum disorder (ASD). This article describes in detail the clinical case of a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by a homozygous mutation in the HADHA gene. The patient underwent instrumental (EEG) and laboratory tests (neurochemical, biochemical, and immunological markers) and subspecialty consultations/examinations (pediatrician, neurologist, clinical psychologist, psychiatric examination). Based on the results of a comprehensive examination and clinical observation, it is possible to assume that the patient has a comorbid or hereditary disorder of mitochondrial beta-oxidation of fatty acids, an autism spectrum disorder, or schizophrenia with onset in childhood.

 

Keywords: long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, mutation in the HADHA gene, autism spectrum disorder, childhood-onset schizophrenia.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

For citation: Shushpanova O.V., Boksha I.S., Zozulya S.A. Autism spectrum disorder in an adolescent with deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase of fatty acids caused by a mutation in the HADHA gene in a homozygous state (presentation of a clinical case). Siberian Herald of Psychiatry and Addiction Psychiatry.2025; 4 (129): 105-116. https://doi.org/10.26617/1810-3111-2025-4(129)-105-116

 

REFERENCES

  1. Strandqvist A, Haglind CB, Zetterström RH, Nemeth A, von Döbeln U, Stenlid MH, Nordenström A. Neuropsychological development in patients with long-chain 3-hydroxyacyl-COA dehydrogenase (LCHAD) deficiency. JIMD Rep. 2016;28:75-84.https://doi.org/10.1007/8904_2015_505. Epub 2015 Nov 7. PMID: 26545880; PMCID: PMC5059195.
  2. Prasun P, LoPiccolo MK, Ginevic I. Long-Chain Hydroxyacyl-CoA Dehydrogenase deficiency / trifunctional protein deficiency. 2022 Sep 1. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK583531/
  3. Haglind CB, Stenlid MH, Ask S, Alm J, Nemeth A, Döbeln U, Nordenström A. Growth in long-chain 3-hydroxyacyl-COA dehydrogenase deficiency. JIMD Rep. 2013;8:81-90. https://doi.org/10.1007/8904_2012_164. Epub 2012 Jul 6. PMID: 23430524; PMCID: PMC3565647.
  4. Rücklová K, Hrubá E, Pavlíková M, Hanák P, Farolfi M, Chrastina P, Vlášková H, Kousal B, Smolka V, Foltenová H, Adam T, Friedecký D, Ješina P, Zeman J, Kožich V, Honzík T. Impact of newborn screening and early dietary management on clinical outcome of patients with long chain 3-hydroxyacyl-coa dehydrogenase deficiency and medium chain acyl-coa dehydrogenase deficiency-a retrospective nationwide study. Nutrients. 2021 Aug 24;13(9):2925. https://doi.org/10.3390/nu13092925. PMID: 34578803; PMCID: PMC8469775.
  5. Rajtar M. 'Small' data, isolated populations, and new categories of rare diseases in Finland and Poland. Anthropol Med. 2023 Mar;30(1):1-16. https://doi.org/10.1080/13648470.2022.2152633. Epub 2023 Feb 9. PMID: 36760192.
  6. Schwantje M, Fuchs SA, de Boer L, Bosch AM, Cuppen I, Dekkers E, Derks TGJ, Ferdinandusse S, Ijlst L, Houtkooper RH, Maase R, van der Pol WL, de Vries MC, Verschoof-Puite RK, Wanders RJA, Williams M, Wijburg F, Visser G. Genetic, biochemical, and clinical spectrum of patients with mitochondrial trifunctional protein deficiency identified after the introduction of newborn screening in the Netherlands. J Inherit Metab Dis. 2022 Jul;45(4):804-818. https://doi.org/10.1002/jimd.12502.
  7. Mitochondrial β-oxidation disorders. Clinical guidelines. Approved by the Russian Ministry of Health. Moscow, 2021:126(in Russian).
  8. Saudubray JM, Martin D, de Lonlay P, Touati G, Poggi-Travert F, Bonnet D, Jouvet P, Boutron M, Slama A, Vianey-Saban C, Bonnefont JP, Rabier D, Kamoun P, Brivet M. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis. 1999 Jun;22(4):488-502. https://doi.org/10.1023/a:1005556207210. PMID: 10407781.
  9. Brown A, Crowe L, Andresen BS, Anderson V, Boneh A. Neurodevelopmental profiles of children with very long chain acyl-CoA dehydrogenase deficiency diagnosed by newborn screening. Mol Genet Metab. 2014 Dec;113(4):278-82. https://doi.org/10.1016/j.ymgme.2014.10.005. Epub 2014 Oct 12. PMID: 25456746.
  10. Hsu HW, Zytkovicz TH, Comeau AM, Strauss AW, Marsden D, Shih VE, Grady GF, Eaton RB. Spectrum of medium-chain acyl-CoA dehydrogenase deficiency detected by newborn screening. Pediatrics. 2008 May;121(5):e1108-14. https://doi.org/10.1542/peds.2007-1993. PMID: 18450854.
  11. Iafolla AK, Thompson RJ Jr, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr. 1994 Mar;124(3):409-15. https://doi.org/10.1016/s0022-3476(94)70363-9. PMID: 8120710.
  12. Joy P, Black C, Rocca A, Haas M, Wilcken B. Neuropsychological functioning in children with medium chain acyl coenzyme a dehydrogenase deficiency (MCADD): the impact of early diagnosis and screening on outcome. Child Neuropsychol. 2009 Jan;15(1):8-20.https://doi.org/10.1080/09297040701864570.PMID: 18608229.
  13. Waisbren SE, Landau Y, Wilson J, Vockley J. Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening. Dev Disabil Res Rev. 2013;17(3):260-8. https://doi.org/10.1002/ddrr.1119. PMID: 23798014; PMCID: PMC4137760.
  14. den Boer ME, Wanders RJ, Morris AA, IJlst L, Heymans HS, Wijburg FA. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics. 2002 Jan;109(1):99-104. https://doi.org/10.1542/peds.109.1.99. PMID: 11773547.
  15. Faulkner MS. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: a case example in developmental disabilities. J Pediatr Nurs. 1999 Dec;14(6):359-68. https://doi.org/10.1016/S0882-5963(99)80065-7. PMID: 10638050.
  16. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res. 1983;22(2):79-131.https://doi.org/10.1016/0163-7827(83)90004-8. PMID: 6348799.
  17. Carver JD, Benford VJ, Han B, Cantor AB. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res Bull. 2001 Sep 15;56(2):79-85. https://doi.org/10.1016/s0361-9230(01)00551-2. PMID:11704343.
  18. Svennerholm L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res. 1968 Sep;9(5):570-9. PMID: 4302302.
  19. de Urquiza AM, Liu S, Sjöberg M, Zetterström RH, Griffiths W, Sjövall J, Perlmann T. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science. 2000 Dec 15;290(5499):2140-4. https://doi.org/10.1126/science.290.5499.2140. PMID:11118147.
  20. German OL, Monaco S, Agnolazza DL, Rotstein NP, Politi LE. Retinoid X receptor activation is essential for docosahexaenoic acid protection of retina photoreceptors. J Lipid Res. 2013 Aug;54(8):2236-2246.https://doi.org/10.1194/jlr.M039040. Epub 2013 May 30. PMID: 23723389; PMCID: PMC3708373.
  21. Heaton AE, Meldrum SJ, Foster JK, Prescott SL, Simmer K. Does docosahexaenoic acid supplementation in term infants enhance neurocognitive functioning in infancy? Front Hum Neurosci. 2013 Nov 20;7:774. https://doi.org/10.3389/fnhum.2013.00774. PMID: 24312040; PMCID: PMC3834239.
  22. Bakermans AJ, Geraedts TR, van Weeghel M, Denis S, João Ferraz M, Aerts JM, Aten J, Nicolay K, Houten SM, Prompers JJ. Fasting-induced myocardial lipid accumulation in long-chain acyl-CoA dehydrogenase knockout mice is accompanied by impaired left ventricular function. Circ Cardiovasc Imaging. 2011 Sep;4(5):558-65.https://doi.org/10.1161/CIRCIMAGING.111.963751. Epub 2011 Jul 7. PMID: 21737602.
  23. Harding CO, Gillingham MB, van Calcar SC, Wolff JA, Verhoeve JN, Mills MD. Docosahexaenoic acid and retinal function in children with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 1999 May;22(3):276-80. https://doi.org/10.1023/a:1005502626406. PMID: 10384386; PMCID: PMC2694039.
  24. Tucci S. An altered sphingolipid profile as a risk factor for progressive neurodegeneration in long-chain 3-hydroxyacyl-CoA deficiency (LCHADD). Int J Mol Sci. 2022 Jun 27;23(13):7144. https://doi.org/10.3390/ijms23137144. PMID: 35806149; PMCID: PMC9266703.
  25. Garmendia JV, De Sanctis CV, Das V, Annadurai N, Hajduch M, De Sanctis JB. Inflammation, autoimmunity and neurodegenerative diseases, therapeutics and beyond. Curr Neuropharmacol. 2024;22(6):1080-1109.https://doi.org/10.2174/1570159X22666231017141636.PMID: 37898823; PMCID: PMC10964103.
  26. KlyushnikTP, AndrosovaLV, SimashkovaNV, ZozulyaSA, OtmanIN, ShushpanovaOV, BrusovOS. Clinical and laboratory diagnosis of autism spectrum disorders in children. Laboratory Service.2016;5(2):22‑27. https://doi.org/10.17116/labs20165222-27(in Russian).
  27. Vockley J. Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care. 2020 Aug;26(7 Suppl):S147-S154.https://doi.org/10.37765/ajmc.2020.88480. PMID: 32840329; PMCID: PMC9850137.
  28. Ørngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforêt P. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology. 2014 Feb 18;82(7):607-13.https://doi.org/10.1212/WNL.0000000000000118. Epub 2014 Jan 22. PMID: 24453079; PMCID: PMC3963421.
  29. Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, Das A, Haase C, Hennermann JB, Karall D, de Klerk H, Knerr I, Koch HG, Plecko B, Röschinger W, Schwab KO, Scheible D, Wijburg FA, Zschocke J, Mayatepek E, Wendel U. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis. 2009 Aug;32(4):488-97. https://doi.org/10.1007/s10545-009-1125-9. Epub 2009 Apr 29. PMID: 19399638.